Table 1.
Summary of vaccine efficacy findings from clinical trials of rotavirus vaccines (RV1 and RV5)
| Location | Vaccine | Vaccine Efficacy (95% Cl) | Rotavirus Gastroenteritis Severity |
| High and middle income | |||
| Latin America and Finland3 | RV1 | 85% (72–92) | Severe (Vesikari score ≥11) |
| Europe67 | RV1 | 87% (80–92) | Any severity |
| Asia (Hong Kong, Singapore, Taiwan)68 | RV1 | 96% (85–100) | Severe (Vesikari score ≥11) |
| Japan69 | RV1 | 92% (62–99) | Severe (Vesikari score ≥11) |
| United States and Finland4 | RV5 | 98% (88–100) | Severe G1–G4 (Clark score >16) |
| 74% (67–80) | Any severity (G1–G4) | ||
| Middle-low and low income | |||
| Africa (South Africa and Malawi)7 | RV1 | 59% (36–74) | Severe (Vesikari score ≥11) |
| Africa (Kenya, Ghana, Mali)5 | RV5 | 64% (40–79) | Severe (Vesikari score ≥11) |
| Asia (Vietnam and Bangladesh)6 | RV5 | 51% (13–73) | Severe (Vesikari score ≥11) |